Search Site:

Global Activities

General

Manufacture & Supply

Laboratory Facilities

General

Global Activities

27/01/2009

Dexcel Pharma conducts its operations in 20 countries worldwide through local subsidiaries and distributors:

In the US, Dexcel Pharma Technologies, Ltd. was first to file, obtain approval for, and launch generic Omeprazole OTC 20mg to the 26 largest chain pharmacy/drugstores, in cooperation with Perrigo (Prilosec^® $800m market).

In the UK, Dexcel-Pharma Limited is a Top 10 generics company, a market leader in several product categories, and has an excellent long-term relationship with primary chains.

In Germany, Dexcel Pharma GmbH has secured contracts for 25 molecules in 66 dosages with 16 sick funds. Its expanding product range will bring further growth through comprehensive, aggressive bidding in all future sick fund tenders.

Dexcel Pharma's strategy is"first-to-file" in the US and "day one" in the EU.

Dexcel Pharma has obtained approval for and launched Omepazole Rx 20mg in Australia, the first of many products to be launched there.

Dexcel Pharma's innovative dental product PerioChip^® is marketed to dentists in the US (NDA), 12 EU member states and Singapore, and is soon to be launched in Korea.

Search Site:

General

Global Activities 27/01/2009

Global Activities

27/01/2009